CHRONIC MYELOMONOCYTIC LEUKEMIA

This study is for people with blood cancers like leukemia or lymphoma who need a stem cell transplant from an unrelated donor. It compares two ways to prevent graft-versus-host disease (GVHD), a serious complication where donor cells attack the patient's body. One method uses a d…

This phase 3 trial tests whether adding IMM01 (timdarpacept) to standard azacitidine helps people with newly diagnosed chronic myelomonocytic leukemia (CMML). About 170 adults will receive either the combo or a placebo plus azacitidine. The main goals are complete remission and o…

This study tests a combination of two drugs, enasidenib and azacitidine, in people with a high-risk form of myelodysplastic syndrome (MDS) that has a specific IDH2 gene mutation. The goal is to see if the treatment is safe and can shrink or control the cancer. About 63 participan…

This study tests a combination of two drugs, enasidenib and azacitidine, for people with a specific genetic form of acute myeloid leukemia (IDH2-mutated) that has come back or stopped responding to treatment. The goal is to see if the combo can shrink or control the cancer. About…

This phase 2 trial tests whether adding high-dose intravenous vitamin C to standard chemotherapy can help treat blood cancers like lymphoma that have returned or not responded to treatment, as well as related conditions. About 80 adults will receive the combination to see if it i…

This study tests a drug called olutasidenib in 15 people with specific blood conditions (CCUS, lower-risk MDS, or CMML) that have an IDH1 mutation. The goal is to see if the drug can help control the disease and to check for side effects. Participants must have a confirmed diagno…

This early-stage study tests a new drug called STX-0712 in people with advanced chronic myelomonocytic leukemia (CMML) or acute myeloid leukemia (AML) who have run out of standard treatments. The main goals are to find a safe dose and check for side effects. About 105 participant…

This early-phase study tests whether adding an experimental drug (defactinib) to an approved oral treatment (decitabine/cedazuridine) is safe and tolerable for people with high-risk myelodysplastic syndromes, certain acute myeloid leukemias, and chronic myelomonocytic leukemia. A…

This early-phase trial is testing whether the drug olutasidenib can safely prevent blood cancers (AML, MDS, or CMML) from coming back after a donor stem cell transplant. The study includes 15 adults whose cancers have a specific IDH1 gene change. Participants will take olutasiden…

This study tests a radioactive antibody (211At-BC8-B10) given before a donor stem cell transplant for people with high-risk leukemias or related blood cancers. The antibody targets cancer cells and delivers radiation to help kill them while sparing healthy cells. The goal is to f…

This study tests a new combination of three drugs (cyclophosphamide, tacrolimus, and ruxolitinib) to prevent graft-versus-host disease (GVHD) in people receiving a stem cell transplant for blood cancers like leukemia. The goal is to see if this approach can reduce severe GVHD and…

This study tests a two-step method using lower doses of radiation and chemotherapy before a stem cell transplant for people with various blood cancers or bone marrow failure. The goal is to see if this gentler approach reduces the chance of dying from the transplant itself. About…

This study tests whether giving patients their own specially matched natural killer (NK) cells after chemotherapy and a cord blood transplant can help keep blood cancers like leukemia and lymphoma from coming back. About 100 adults with various blood cancers will receive NK cells…

This study tests a low-dose weekly combination of two FDA-approved drugs, decitabine and venetoclax, for people with bone marrow cancers like MDS, AML, and CMML. The goal is to see if this gentler schedule can keep patients on treatment longer with fewer interruptions. About 91 a…

This study tests a drug called canakinumab in people with low- or intermediate-risk myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML). The drug is an antibody that may slow cancer growth. About 76 adults will receive injections to see if it improves blood c…

This early-stage trial tests a new treatment called CD4CAR T cells for people with a rare blood cancer called CMML that has come back or not responded to standard therapy. The treatment uses a patient's own immune cells, modified in a lab to target and attack cancer cells. The ma…

This study tests a stem cell transplant from a half-matched donor for people with blood cancers. Before the transplant, patients receive chemotherapy and low-dose radiation to prepare the body. The goal is to see if this approach helps the new stem cells grow and fight cancer wit…

This early-phase study tests whether adding the drug momelotinib to standard treatment (azacitidine) can better control rare blood cancers like chronic myelomonocytic leukemia and chronic neutrophilic leukemia. About 18 adults will take the combination for up to 24 months. The go…

This study tests an oral drug (ASTX030) that combines two medicines to treat certain blood cancers like MDS and AML. The goal is to see if taking a pill works as well as getting a shot, and if it can be safely combined with another drug (venetoclax) for AML. About 316 adults will…

This study tests a new drug called axatilimab, alone or with another drug (azacitidine), for people with advanced blood cancers like MPN, MPN/MDS overlap, or high-risk CMML. Axatilimab is an antibody that blocks a protein on white blood cells to slow cancer growth. The trial aims…

This study tests a new experimental drug called EP0042, alone or with other cancer treatments, in adults with advanced acute myeloid leukemia (AML) or related blood cancers. The main goal is to find a safe dose that might work against the cancer. About 70 people will take part in…

This study tests a treatment for adults aged 60 and older with newly diagnosed, high-risk acute myeloid leukemia (AML) or similar blood cancers. The approach combines strong chemotherapy (FLAG-Ida) with a donor stem cell transplant shortly after, aiming to shorten the dangerous p…

This early-phase trial tests a new treatment for children and adults with acute leukemia that has come back or not responded after a donor stem cell transplant. The treatment uses specially engineered immune cells (T cells) from the original donor that are trained to recognize an…

This study tests whether adding venetoclax to standard chemotherapy before a stem cell transplant can help people with high-risk acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) live longer without their cancer coming back. About 324 adults aged 18 to 70 will receiv…

This study tests a radioactive antibody (211At-BC8-B10) followed by a donor stem cell transplant for people with high-risk leukemia or myelodysplastic syndrome (MDS) that has come back or not responded to treatment. The antibody targets cancer cells and delivers radiation, then c…

This study looks at whether measuring certain proteins in the blood can help predict outcomes for people with acute myeloid leukemia, high-risk myelodysplastic syndrome, or chronic myelomonocytic leukemia who receive a gentler type of chemotherapy. Researchers will collect blood …